RxDoctor Payments Data

James Anderson, MD

Neurology · Clarksville, TNNPI 1689671802

Payments from drug & device makers

$18,139in general payments, 2019–2025

Across 1,122 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$1K
  • SK Life Science, Inc.$1K
  • Biogen$1K
  • Lilly USA, LLC$1K
  • Lundbeck LLC$1K
  • plus $10K from 53 others

What the payments were for

  • Food & beverage$18,01599%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)146$1,609
Neurocrine Biosciences, Inc.62$1,316
SK Life Science, Inc.70$1,273
Biogen61$1,236
Lilly USA, LLC69$1,188
Lundbeck LLC44$1,052
Teva Pharmaceuticals USA, Inc.98$880
Argenx US, Inc.32$837
Novartis51$832
MDD US Operations, LLC63$816
CSL Behring38$792
Pfizer53$695
Acadia Pharmaceuticals Inc29$458
Amgen24$440
Supernus Pharmaceuticals, Inc.51$368
EMD Serono, Inc.19$335
Sumitomo Pharma America, Inc.16$325
AstraZeneca14$245
Avanir Pharmaceuticals, Inc.12$242
Otsuka America Pharmaceutical, Inc.13$233
Johnson & Johnson15$208
Jazz Pharmaceuticals Inc.10$200
Eisai Inc.12$197
Biohaven Pharmaceuticals, Inc.11$193
Biohaven Pharmaceutical Holding Company Ltd.18$189
Neurelis, Inc.9$175
Axsome Therapeutics, Inc.7$161
Grifols USA, LLC7$155
Catalyst Pharmaceuticals, Inc.7$144
Takeda Pharmaceuticals U.S.A., Inc.4$112
Astellas Pharma US Inc1$100
Octapharma USA, Inc.2$92
Avadel CNS Pharmaceuticals, LLC3$92
Alnylam Pharmaceuticals Inc.3$83
Amneal Pharmaceuticals LLC4$80
TG Therapeutics, Inc.4$74
Harmony Biosciences LLC4$64
Merck3$59
Scilex Pharmaceuticals Inc.3$53
Genentech USA, Inc.3$46
Inspire Medical Systems, Inc.2$45
UCB, Inc.1$40
Upsher-smith Laboratories LLC2$37
Banner Life Sciences, LLC2$35
Avion Pharmaceuticals2$34
Assertio Therapeutics, Inc.2$32
Tanabe Pharma America, Inc.2$27
Collegium Pharmaceutical, Inc.2$27
Arbor Pharmaceuticals, Inc.2$26
Vanda Pharmaceuticals Inc.1$22
Bayer1$21
Xeris Pharmaceuticals, Inc.1$21
E.r. Squibb & Sons, L.L.C.1$20
Novo Nordisk1$20
Travere Therapeutics, Inc.1$20
Almatica Pharma LLC1$17
Kyowa Kirin, Inc.1$16
Adamas Pharmaceuticals, Inc.1$15
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$15

How this compares

$18,139 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$408,097
Medicare patients
597
Services billed
4,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate33$272,120
XcopriCenobamate117$151,475
BriviactBrivaracetam47$67,979
AptiomEslicarbazepine Acetate32$49,737
Nurtec OdtRimegepant Sulfate30$34,613
Aimovig AutoinjectorErenumab-Aooe20$29,489
SunosiSolriamfetol Hcl19$26,626
QuliptaAtogepant21$25,374
BotoxOnabotulinumtoxina13$21,174
Emgality PenGalcanezumab-Gnlm16$19,896
NuedextaDextromethorphan Hbr/Quinidine14$17,963
UbrelvyUbrogepant16$17,841
Rivastigmine81$14,822
Gabapentin1,038$10,946
Levetiracetam339$10,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,316$272,12033 claims
SK Life Science, Inc.Xcopri$1,273$151,475117 claims
UCB, Inc.Briviact$40$67,97947 claims
AbbVieQulipta, Botox, Ubrelvy$1,609$64,38950 claims
PfizerNurtec Odt$695$34,61330 claims
Axsome Therapeutics, Inc.Sunosi$161$26,62619 claims
Avanir Pharmaceuticals, Inc.Nuedexta$242$17,96314 claims
MerckBelsomra$59$5,29312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Clarksville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →